A detailed history of Rice Hall James & Associates, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 467,759 shares of ALKS stock, worth $12.9 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares
467,759
Previous 400,809 16.7%
Holding current value
$12.9 Million
Previous $10.8 Million 3.9%
% of portfolio
0.73%
Previous 0.66%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$23.21 - $27.24 $1.55 Million - $1.82 Million
66,950 Added 16.7%
467,759 $11.3 Million
Q1 2024

Apr 23, 2024

BUY
$26.4 - $32.56 $10 Million - $12.4 Million
380,507 Added 1874.23%
400,809 $10.8 Million
Q4 2023

Feb 08, 2024

BUY
$23.37 - $28.68 $474,457 - $582,261
20,302 New
20,302 $563,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.52B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.